The Effect of TRADJENTA (LINAGLIPTIN) on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects

Trial Profile

The Effect of TRADJENTA (LINAGLIPTIN) on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Linagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Nov 2017 Planned End Date changed from 1 Aug 2016 to 1 May 2018.
    • 02 Nov 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Feb 2018.
    • 02 Nov 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top